Evidence map›Paper›PMID 35907048›Full record

ArticleJournal of assisted reproduction and genetics2022

Prevention of intrauterine fetal growth restriction by administrating C1q/TNF-related protein 6, a specific inhibitor of the alternative complement pathway.

Mayu Kurokawa, Ai Takeshita, Shu Hashimoto, Masayasu Koyama, Yoshiharu Morimoto, Daisuke Tachibana

Open access · greenAbstract read
In one paragraph

Article in Journal of assisted reproduction and genetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Mesenchymal stem cells for recurrent miscarriage.Journal of translational medicine · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Exploring CTRP6: a biomarker and therapeutic target in metabolic diseases.American journal of physiology. Endocrinology and metabolism · 2025
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Mayu KurokawaWomen's Lifecare Medicine, Obstetrics and Gynecology, School of Medicine, Osaka City University, 545-8585, Osaka, Japan.
Ai TakeshitaGraduate School of Medicine, Reproductive Science, Osaka City University, Osaka, 545-8585, Japan.
Shu HashimotoGraduate School of Medicine, Reproductive Science, Osaka City University, Osaka, 545-8585, Japan. hashimoto@ivfnamba.com.ORCID http://orcid.org/0000-0001-9083-1403
Masayasu KoyamaWomen's Lifecare Medicine, Obstetrics and Gynecology, School of Medicine, Osaka City University, 545-8585, Osaka, Japan.
Yoshiharu MorimotoHORAC Grand Front Osaka Clinic, Osaka, 530-0011, Japan.
Daisuke TachibanaWomen's Lifecare Medicine, Obstetrics and Gynecology, School of Medicine, Osaka City University, 545-8585, Osaka, Japan.
Osaka City University · JPOsaka Nishi Clinic · JP

Funding

the Japan Society for the Promotion of Science 18H06257the Japan Society for the Promotion of Science 19K18649the Japan Society for the Promotion of Science 20K09674
6 · The paper itself

Abstract

purposeThe latest treatments do not sufficiently prevent miscarriage and fetal growth restriction (FGR) in pregnant women. Here, we assessed the effects of a human protein, CTRP6, that specifically inhibits the activation of the alternative complement pathway on miscarriage, fetal and placental development.

methodsPregnant CBA/J mice mated with DBA/2 male mice as a model of spontaneous abortion and FGR were randomly divided into the control and CTRP6 groups. In the CTRP6 group, the mice were intravenously administered CTRP6 on days 4.5 and 6.5 post-conception (dpc). The abortion rate and fetal and placental weights on 14.5 dpc were examined. Remodeling of the spiral artery was also assessed.

resultsThe abortion rate in the CTRP6 group (13%) was reduced compared to the control group (21%), but there was no statistical difference. The placental and fetal weights in the CTRP6 group were also heavier than those in the control (P < 0.05). Moreover, the thickness of the blood vessel wall in the CTRP6 group was significantly thinner than that in the control (P < 0.05) and comparable to that in the non-abortion model (CBA/J x BALB). The ratio of the inner-per-the-outer diameter of the spiral artery increased more in the CTRP6 group than that in the control (P < 0.05). As well, the Th1/Th2 cytokine ratio was significantly reduced by CTRP6 treatment.

conclusionsTaken together, the supplementation with a protein that regulates the alternative complement pathway in vivo improves FGR and promotes spiral artery remodeling in a mouse model of miscarriage and FGR.

Indexed as

Abortion, SpontaneousFetal Growth RetardationAdipokinesAnimalsComplement C1qComplement Pathway, AlternativeFemaleMaleMiceMice, Inbred CBAMice, Inbred DBAPlacentaPregnancyAdipokinesComplement C1qCTRP6 protein, mouseAbortionComplement Alternative pathwayRecurrent pregnant failureSpiral artery

Identifiers

PMID35907048
PMCPMC9474761
OpenAlexW4288684700

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.